Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GRID1 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, WB, E |
|---|---|
| Primary Accession | Q9ULK0 |
| Other Accession | Q62640, Q61627, NP_060021.1 |
| Reactivity | Mouse |
| Predicted | Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 112131 Da |
| Antigen Region | 846-875 aa |
| Gene ID | 2894 |
|---|---|
| Other Names | Glutamate receptor ionotropic, delta-1, GluD1, GluR delta-1 subunit, GRID1, KIAA1220 |
| Target/Specificity | This GRID1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 846-875 amino acids from the C-terminal region of human GRID1. |
| Dilution | IHC-P~~1:10~50 WB~~1:1000 E~~Use at an assay dependent concentration. |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | GRID1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | GRID1 (HGNC:4575) |
|---|---|
| Synonyms | KIAA1220 |
| Function | Member of the ionotropic glutamate receptor family, which plays a crucial role in synaptic organization and signal transduction in the central nervous system. Although it shares structural features with ionotropic glutamate receptors, does not bind glutamate as a primary ligand (PubMed:38060673). Instead, forms trans-synaptic adhesion complexes with presynaptic neurexins and cerebellins, regulating NMDA and AMPA receptor activity and influencing synaptic plasticity through signal transduction (By similarity). In the presence of neurexins and cerebellins, forms cation-selective channels that are proposed to be gated by glycine and D-serine (By similarity). However, recent research disputes this ligand-gated cation channel activity (PubMed:39052831). Cation-selective ion channel can be triggered by GRM1 in dopaminergic neurons (By similarity). Also acts as a receptor for GABA, modulating inhibitory synaptic plasticity through non- ionotropic mechanisms (PubMed:38060673). |
| Cellular Location | Postsynaptic cell membrane; Multi-pass membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a subunit of glutamate receptor channels. These channels mediate most of the fast excitatory synaptic transmission in the central nervous system and play key roles in synaptic plasticity.
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Vasan, R.S., et al. JAMA 302(2):168-178(2009)
Treutlein, J., et al. Schizophr. Res. 111 (1-3), 123-130 (2009) :
Guo, S.Z., et al. Schizophr. Res. 93 (1-3), 385-390 (2007) :
Fallin, M.D., et al. Am. J. Hum. Genet. 77(6):918-936(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
